by Jordana Choucair | Jan 28, 2022 | Public Health/Prevention
The Government Accountability Office (GAO) released a report identifying “persistent deficiencies” in HHS’ handling of the COVID-19 pandemic and public health crises dating back to 2007. According to the report, the agency is at “high risk” of fumbling a...
by Jordana Choucair | Jan 28, 2022 | Public Health/Prevention
An analysis from Avalere indicates that millions of Americans are behind on flu, hepatitis, chickenpox, and other routine vaccinations as a result of the COVID-19 pandemic. Adults and adolescents have missed more than 37 million routine vaccinations. Experts are...
by Jordana Choucair | Jan 28, 2022 | Payers
The CMS announced $49.4 million in grant funding to shore up enrollment and retention in Medicaid and the Children’s Health Insurance Program among parents, pregnant people, and children. The funding will go to state and local governments, tribal organizations,...
by Jordana Choucair | Jan 28, 2022 | Life Sciences
Merck & Co. Inc. and Ridgeback Biotherapeutics LP said their COVID-19 antiviral pill, molnupiravir, was active against the Omicron variant in six lab studies. The drug’s effectiveness against Omicron hasn’t yet been studied in human trials. (Article...
by Jordana Choucair | Jan 28, 2022 | Life Sciences
Biogen Inc. will sell its nearly 50 percent stake in Samsung Bioepis, a joint venture with Samsung Biologics to develop biosimilar drugs, to its partner for at least $2.25 billion. The deal will give Biogen access to $1 billion in cash upon closing as the pharma...
by Jordana Choucair | Jan 27, 2022 | Payers
During a recent webinar, Third Horizon Strategies Managing Director Cheryl Matochik discussed what the employee benefits industry can expect to see in 2022. Cheryl stated that the industry is “moving toward a completely new standard of personalized benefits.” She, and...
Recent Comments